Clinical trial
Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With…
NCT00047281 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00047281 |
|---|---|
| Title | Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma |
| Official title | Trial Of Oral Thalidomide, Celecoxib, Etoposide And Cyclophosphamide In Adult Patients With Relapsed Or Progressive Malignant Gliomas |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH Schering-Plough Industry Celgene |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | celecoxib, cyclophosphamide, etoposide, thalidomide |
| Start date | Mar 1, 2004 |
| Primary completion | Aug 1, 2005 |
| Completion | Feb 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 11, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: